LIFE Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 3.70%
Insider Buying (Last 12 Months): $132,650.00
Insider Selling (Last 12 Months): $0.00

aTyr Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at aTyr Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

aTyr Pharma Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 06/4/2024 10:09 PM ET

This chart shows the closing price history over time for LIFE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

SEC Filings (Institutional Ownership Changes) for aTyr Pharma (NASDAQ:LIFE)

61.72% of aTyr Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LIFE by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total InflowsTotal Outflows
aTyr Pharma logo
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Read More on aTyr Pharma

Today's Range

Now: N/A

50 Day Range

MA: $1.76
Low: $1.57
High: $2.07

52 Week Range

Now: N/A

Volume

269,400 shs

Average Volume

514,103 shs

Market Capitalization

$131.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Who are the company insiders with the largest holdings of aTyr Pharma?

aTyr Pharma's top insider investors include:
  1. Paul Schimmel (Director)
  2. Sanjay Shukla (CEO)
  3. Timothy Coughlin (Director)
  4. Jill Marie Broadfoot (CFO)
Learn More about top insider investors at aTyr Pharma.